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A B S T R A C T
This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:
To assess whether intermediate hyperglycaemia is a predictor for the development of type 2 diabetes mellitus (T2DM).
B A C K G R O U N D
’Prediabetes’, ’borderline diabetes’, the ’prediabetic stage’, ’high
risk of diabetes’, ’dysglycaemia’ or ’intermediate hyperglycaemia’
are often characterised by various measurements of elevated blood
glucose concentrations, such as (isolated) impaired fasting glucose
(IFG), (isolated) impaired glucose tolerance (IGT), (isolated) el-
evated glycosylated haemoglobin A1c (HbA1c) or combinations
of these conditions (WHO/IDF 2006). Elevated blood glucose
levels that indicate hyperglycaemia are too high to be considered
normal, but are below the diagnostic threshold for type 2 dia-
betes mellitus (T2DM). Therefore, due to the continuous gly-
caemic spectrum from the normal to the diabetic stage, a sound
evidence base is needed to define glycaemic thresholds for people
at high risk of T2DM, especially because dysglycaemia is com-
monly an asymptomatic condition, and naturally often remains
’undiagnosed’ (CDC 2015). The various terms used to describe
the diverse stages of hyperglycaemia may cause people to have
marked emotional reactions. For example, the term ’prediabetes’
may imply (at least for non-experts) that the disease diabetes is
unavoidable, whereas (high) risk of diabetes has the positive con-
notation of possibly being able to avoid the disease altogether. In
addition to the disputable construct of intermediate health states
termed ’prediseases’ (Viera 2011), many people may associate the
label ’prediabetes’ with dire consequences. Alternatively, any di-
agnosis of ’prediabetes’ may be an opportunity to review, for ex-
ample, eating habits and physical activity levels, thus enabling ’af-
fected’ individuals to actively change their way of life.
Several institutional bodies like theAmericanDiabetesAssociation
(ADA) and the World Health Organization (WHO) established
commonly-used criteria to define people who are at a high risk of
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developing T2DM.
• In 1979, the National Diabetes Data Group (NDDG)
described glucose intolerance as a concept of a metabolic state
intermediate between normoglycaemia and diabetes (NDDG
1979). NDDG defined this IGT by an elevated two-hour plasma
glucose concentration (7.8 mmol/L to 11.1 mmol/L or 140 mg/
dL to 199 mg/dL) two hours after a 75 g glucose load on the oral
glucose tolerance test (OGTT).
• In 1997, the Expert Committe on the Diagnosis and
Classification of Diabetes Mellitus and later the WHO defined
two intermediate states of glucose regulation existing between
regular glucose homeostasis and diabetes: IGT was diagnosed
two hours after a 75 g OGTT by a plasma glucose level of 7.8
mmol/L to 11.1 mmol/L (140 mg/dL to 199 mg/dL) or by the
concept of IFG (ADA 1997; WHO 1999). The initial definition
of IFG was a fasting plasma glucose (FPG) level of 6.1 mmol/L
to 6.9 mmol/L (110 mg/dL to 125 mg/dL). In 2003, the ADA
reduced the lower threshold to 5.6 mmol/L (100 mg/dL) (ADA
2003). However, the WHO did not endorse this lower cut-off
point for IFG (WHO/IDF 2006).
• More recently, an elevated HbA1c has been introduced to
identify people at high risk of developing T2DM. In 2009, the
International Expert Committee (IEC) suggested HbA1c
measurements of 6.0% to 6.4% (42 mmol/mol to 46 mmol/
mol) to identify people at a high risk of T2DM (IEC 2009). In
2010, the ADA re-defined this HbA1c level as 5.7% to 6.4% (39
mmol/mol to 46 mmol/mol) (ADA 2010), a decision not
endorsed by WHO, IEC or other organisations.
The various glycaemic tests do not identify the same people at
risk, as there is an imperfect overlap among the glycaemic modali-
ties available to define intermediate hyperglycaemia (Cheng 2006;
Gosmanov 2014; Morris 2013; Selvin 2011). Unlike IFG and
IGT, HbA1c reflects longer-term glycaemic control, i.e. how a
person’s blood glucose concentrations have been during the pre-
ceding two to three months (Inzucchi 2012). Compared with IFG
and IGT measurements, HbA1c assessments have less intraper-
sonal variability when repeated. However, haemoglobin variants,
genetic haemoglobinopathies, thalassemias and iron deficiency
anaemia substantially influence HbA1c measurements (Mostafa
2011). The FPG thresholds of defining IFG and the question
whether HbA1c is an adequate tool to diagnose intermediate
hyperglycaemia are still debated (Buysschaert 2011; Buysschaert
2016). In studies investigating the risk of intermediate hypergly-
caemia the effects are probably underestimated if time-dependent
effects are not taken into account (Lind 2009). On the other hand,
it is questioned whether HbA1c is the right outcome for studies
of diabetes at all (Lipska 2017).
Also, IFG and IGTdiffer in their age and sex distribution and both
increase with advancing age (Nathan 2007), as glucose tolerance
deteriorates with age (Gale 2013). Ethnicity and geography are
additional important features: the prevalence of an elevatedHbA1c
in non-Hispanic black people is twice as high as in non-Hispanic
white people and the opposite is true for IGT (Selvin 2011; Ziemer
2010). The number of people identified in South Asian compared
with European cohorts and the associated cardiovascular disease
(CVD) risk associated with intermediate hyperglycaemia depends
on how ’prediabetes’ is diagnosed (Eastwood 2016).
The increase in T2DM results from an interaction between ge-
netic and environmental factors reflecting behavioural changes
over time such as decreased physical activity levels and increased
body weight (DeFronzo 2011; Nathan 2007). Both IFG and IGT
are insulin-resistant states and insulin resistance is thought to be
the core defect in T2DM: people with (isolated) IFG predom-
inantly have β-cell dysfunction with impaired insulin secretion
(DeFronzo 1989), moderate hepatic insulin resistance, but near-
normal muscle insulin sensitivity. The consequence is an excessive
fasting hepatic glucose production followed by an elevated FPG.
During an OGTT the early insulin response (0 to 30/60 min) is
impaired, resulting in an excessive early rise in post-load glucose
(PG). The late insulin response (60 to 120 min) appears intact and
the two-hour PG returns to its approximately starting FPG level
(DeFronzo 2011; Nathan 2007). People with (isolated) IGT have
normal to slightly reduced hepatic insulin sensitivity and moder-
ate to severe muscle insulin resistance (Abdul-Ghani 2006; Jensen
2002). During an OGTT the early and the late insulin response
are impaired. Hyperglycaemia is progressive and prolonged after
the glucose load, the two-hour PG remains above its starting FPG
level (DeFronzo 2011; Nathan 2007).
There are some known risk indicators for the development of
T2DM, e.g. a positive family history, gestational diabetes mellitus,
obesity, ethnicity, polycystic ovarian syndrome, impaired insulin
secretion and insulin resistance, abnormal coagulation factors and
endothelial dysfunction.However, the evidence base for theweight
of a single risk indicator and the interplay of various factors is still
under investigation. Type 2 diabetes mellitus is a rather complex
metabolic state and could be described as an asymptomatic risk
factor for a future disease (Yudkin 2016), and hence prediabetes a
risk factor for another risk factor (Nathan 2007).
Diabetes is a category, whereas IFG and IGT reflect a continuous
variable with more or less arbitrarily chosen cut-off points (Yudkin
1990; Yudkin 2014). The reduced lower threshold of 5.6 mmol/L
(100 mg/dL) to define IFG by ADA 2003 substantially increased
the prevalence of IFG with potential significant impact on public
health and socioeconomic issues (Davidson 2003; Yudkin 2014;
Yudkin 2016). Others argue that even if it was only possible to
delay the onset of diabetes by detecting and treating ’prediabetes’,
substantial benefitsmight ensue (Cefalu 2016). Interestingly, some
people with intermediate hyperglycaemiawill not developT2DM,
and some people will return or ’regress’ to normoglycaemia. In
the Diabetes Prevention Program (DPP) the hazard ratio (HR)
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of developing T2DM was 0.44 (95% confidence interval (CI)
0.37 to 0.55) in people having at least one normal OGTT during
the DPP compared with people who never regressed to normo-
glycaemia during the DPP (Perreault 2012; Perreault 2014). The
ADA associated regression with remission and defined it as a par-
tial or complete diabetes remission of glycaemic measurements for
at least one year without pharmacological or surgical interventions
(Buse 2009). This could have significant impact on “the therapeu-
tic strategy fromdiabetes prevention and lifelong glucose-lowering
treatment to induction of regression and monitoring for relapse”
(Yakubovich 2012).
O B J E C T I V E S
To assess whether intermediate hyperglycaemia is a predictor for
the development of type 2 diabetes mellitus (T2DM).
M E T H O D S
Criteria for considering studies for this review
Study design
To investigate intermediate hyperglycaemia as a possible predictor
(exposition) for the development of T2DM, the adequate study
design to investigate the long-term transitionbetween ’prediabetes’
and T2DM is a prospective cohort study. Prognostic studies are
studies investigating variables which are predictive of future events
as well as studies of aetiological factors (Altman 2001), which is
why this review is called a prognostic factor exemplar review.
Inclusion criteria
Our outcome of primary interest is the diagnosis of newly devel-
oped T2DM (T2DM incidence) in individuals with intermediate
hyperglycaemia, defined by impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT), elevated HbA1c or any combina-
tion of these.
• T2DM incidence should be diagnosed by blood glucose
measurements such as fasting plasma glucose (FPG), two-hour
post-load glucose (PG) or HbA1c. Dagnosis may be combined
with self-reported diabetes, physician-diagnosed diabetes or use
of antidiabetic medications such as oral hypoglycaemic drugs or
insulin are possible.
• Standard definitions of intermediate hyperglycaemia, i.e.
cut-off values for IFG, IGT or elevated HbA1c as defined by
ADA or WHO (ADA 1997; ADA 2003; ADA 2010; ICH 1997;
IEC 2009; WHO 1998; WHO/IDF 2006).
Exclusion criteria
• Intervention trials and study designs other than prospective
cohort studies.
• Predefined unhealthy cohort at baseline or substantial
comorbidities at baseline (e.g. IFG in individuals with
hypertension or persons with coronary heart disease and IGT).
• Missing data on transition from intermediate
hyperglycaemia to T2DM.
• Follow-up period after baseline assessment not specified.
• Type 2 diabetes incidence evaluated by documents (e.g.
hospital records, retrospective use of databases) or self-report
only.
• Conference abstracts.
Search methods for identification of studies
We will search the following sources from inception of each
database to the specified date.
• Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations and Ovid MEDLINE(R) 1946 to Present.
• Embase 1974 to 2016 Week 50.
• ClinicalTrial.gov.
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (http://
apps.who.int/trialsearch/).
The search strategy will consist of two modules.
• Strategy A: ’Prediabetes’ as predictor for cardiovascular
disease (CVD), mortality, stroke, cancer, micro/macrovascular
complications (population block (prediabetes + prognosis filter))
OR prediabetes risk factors/diagnostic criteria (IFG, IGT,
HbA1c adjacent prognosis terms) AND outcomes (diabetes
complications, micro/macro vascular, mortality)
• Strategy B: ’Prediabetes’ as predictor for diabetes incidence
(population block (prediabetes + prognosis filter)) OR
prediabetes risk factors/diagnostic criteria (IFG, IGT, HbA1c
adjacent prognosis terms) AND outcomes (diabetes incidence).
We will combine both strategies because it is likely that search
results for ’prediabetes’ as a predictor for complications may also
contain data on diabetes incidence. The search strategy has been
developedusing analytical textmining of 21 relevant diabetes com-
plications studies and 22 relevant diabetes incidence studies al-
ready known and selected by review author BR. We used the tools
PubReMiner, TerMine and AntConc and applied the prognosis
filters by the Hedges Team, McMaster University, Canada. Ad-
ditionally, we extracted studies from 16 identified meta-analyses
(Echouffo-Tcheugui 2016; Erqou 2013; Ford 2010; Hope 2016;
Huang 2014;Huang 2014a;Huang 2016; Lee 2012;Morris 2013;
Santos-Oliveira 2011; Sarwar 2010; Schottker 2016; Twito 2015;
Xu 2015; Zhang 2012; Zhong 2016).
The fundamental problem with this type of review is the difficulty
to define the population of interest, i.e. people with intermediate
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hyperglycaemia. We expect a great number of terms describing
this population, such as people with prediabetes, mentioning of
IFG, IGT or HbA1c somewhere in the title or abstract, and terms
like risk factors, predictors, prevalence, incidence or several other
concepts which cannot be foreseen by the development of a regu-
lar search strategy. One way to address this problem is to formu-
late very sensitive search strategies with the consequence of being
faced with tens of thousands database hits, which is currently un-
feasible but may be addressed in the future with advanced data-
mining technologies. Instead, we decided to establish a more spe-
cific search, augmented by thorough identification of systematic
reviews addressing our review question and checking of reference
lists.
We will continuously apply a MEDLINE (via Ovid SP) email
alert service established by theCochraneMetabolic and Endocrine
Disorders (CMED) Group to identify newly published studies
using the same search strategy as described for MEDLINE (for
details on search strategies, see Appendix 1). If we identify new
trials for inclusion, we will evaluate these, and incorporate the
findings into our review (Beller 2013).
If we detect additional key words of relevance during any of the
electronic or other searches, we will modify the electronic search
strategies to incorporate these terms.
Selection of studies
Two review authors (BR and BH) will independently scan the ab-
stract, title, or both, of every record we will retrieve in the litera-
ture searches, to determine which trials to be assessed further. We
will investigate the full text of all potentially relevant articles. We
will resolve discrepancies through consensus or by recourse to a
third review author (MIM). We will prepare a flow diagram of the
number of studies identified and excluded at each stage in accor-
dance with the PRISMA (Preferred reporting items for systematic
reviews andmeta-analyses) flow diagram of trial selection (Liberati
2009).
Data extraction and management
For studies that fulfil our inclusion criteria, one review author
(BR) will extract key study characteristics, inclusion and exclusion
criteria of study participants, stated aim of the study, definitions of
exposure and outcome (normoglycaemia, intermediate glycaemia
and type 2 diabetes incidence), baseline characteristics of study
participants, data on transition from intermediate hyperglycaemia
(as definedby IFG, IGT, elevatedHbA1c or combinations thereof )
to T2DM and assess risk of bias. Another author (MIM) will
check these data extractions and we will resolve any disagreements
by discussion or, if required, by consultation with a third review
author (BH)
Dealing with companion publications
In the event of companion documents or multiple reports of a
prospective cohort study because of different time points investi-
gated, we will focus on the analysis of the publication describing
the longest follow-up from baseline and extract data from shorter
follow-ups in case some expositions were not reported in the pub-
lication on the longest follow-up (e.g. themost recent paper might
describe the association between elevated HbA1c and T2DM in-
cidence, but an older publication might describe the association
between IGT and T2DM incidence). Companion documents or
multiple reports of a primary study will be listed as secondary ref-
erences under the primary reference of the included, ongoing or
excluded study.
Assessment of risk of bias in included studies
One review author (BR) will assess the risk of bias of each included
study and another review author (MIM) will check on accuracy of
this assessment. We will resolve any disagreements by consensus,
or by consultation with a third review author (BH). We will use
a tailored version of the Quality In Prognosis Studies (QUIPS)
tool (Dretzke 2014; Hayden 2013) for assessing risk of bias in
studies of prognostic factors, see Appendix 2. We will investigate
the influence of low risk of bias studies (low risk of bias in all do-
mains, i.e. study participation, study attrition, prognostic factor
measurement, outcome measurement, study confounding, statis-
tical analysis and reporting) versus unclear/high risk of bias studies
(unclear or high risk of bias in at least one of these domains).
Data synthesis
Our primary aim is to provide a transparent overview of the whole
data matrix describing a wide variety of possible associations be-
tween various isolated and combined definitions of intermediate
hyperglycaemia and incident diabetes in dissimilar populations
covering diverse time periods.
First, we will group studies on similar exposure variables, i.e. (iso-
lated) IFG 5.6 mmol/L, (isolated) IFG 6.1 mmol/L, (isolated)
IGT, IFG and IGT, HbA1c 6.0% to 6.4% and HbA1c 5.7% to
6.4%. Then we will subgroup different ethnicities under these ex-
posure variables at comparable follow-up periods.
We expect the following outcome measures.
• Cases (cumulative incidence at follow-up; e.g. 20 new
diabetes cases of 400 people with IFG at baseline (5%)).
• Cumulative incidence rates (cases per 1000 person-years).
• Odds ratios (ORs), rate ratios (RsR), hazard ratios (HRs).
We therefore plan to perform random-effects meta-analyses on
proportions, incidence rate differences (Spittal 2015), incidence
RRs, ORs, relative risks and time-to-event data (HRs).
For incidence rates where reported, we will try to calculate the
person-time exposed from the number of cases occurring in the
exposed (’prediabetic’) group and non-exposed (normoglycaemic)
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group.Wewill then establish amatrix of exposed cases and person-
time as well as non-exposed cases and person time and perform an
incidence rate ratio and/or an incidence rate difference random-
effects meta-analysis.
In case publications report HRs with associated 95% CIs we will
obtain standard errors from these CIs as described in chapter
7.7.7.3 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011) and establish a meta-analysis by means
of the generic inverse-variance method (RevMan 2014). When
possible, we will report both adjusted and unadjusted HRs, but
will primarily use adjusted HRs of multivariate models of studies
incorporating similar covariates (Dretzke 2014).
Assessment of heterogeneity
We expect substantial clinical heterogeneity within the included
prospective cohort studies because of geographical, ethnical and
methodological diversity. We do not intend to address statistical
heterogeneity (inconsistency) by means of the I2 statistic because
this statistic does not tell us howmuch the effect size varies, which
is what people are interested in when asking about the implica-
tions of heterogeneity (Borenstein 2017). Also, the I2 statistic is
problematic in the context of prognostic studies because individ-
ual studies often have large sample sizes resulting in narrow CIs
which can result in high I2 values even if inconsistency between
studies is moderate (Iorio 2015). Instead, we will report the range
of the effects of the random-effects meta-analyses by means of pre-
diction intervals (Borenstein 2017; Higgins 2009; IntHout 2016;
Riley 2015). In a random-effects model meta-analysis the predic-
tion interval reflects the whole distribution of effects across study
populations including what effect is to be expected in a future
study (IntHout 2016; Riley 2015).
Sensitivity analysis
We plan to perform sensitivity analyses to explore the influence of
the following factors (when applicable) on effect sizes by restricting
analysis to the following.
• Taking into account risk of bias, as specified in the
assessment of risk of bias in the included studies section.
• Very long or large studies to establish the extent to which
they dominate the results.
Subgroup analysis
Because we are stratifying analyses by exposure variables and eth-
nicity, which we think are the main features creating heterogene-
ity, we do not plan to perform subgroup analyses. In case we are
able to extract a meaningful number of studies (at least 10 studies)
specifying diabetes incidence data, we plan to carry out subgroup
analyses with investigation of interactions for the subgroups:
• age, depending on data;
• gender.
Should we be able to extract T2DM incidence data for children
and adolescents, we will separately report results for this group of
study participants.
Quality of evidence
We will create a ’Summary of findings’ table using Review Man-
ager 5 (RevMan 5.3) table editor (RevMan 2014). We will use an
adapted version of the GRADE framework of prognostic factor
research (Huguet 2013) for describing the influence of our expo-
sition variables IFG, IGT, elevated HbA1c and IFG/IGT on the
development of T2DM.Wewill justify all decisions to downgrade
the quality of trials using footnotes and we will make comments
to aid the reader’s understanding of the Cochrane review where
necessary.
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (Ovid SP)
Whole strategy (combining strategy A: ’prediabetes’ as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovas-
cular complications and strategy B: ’prediabetes’ as predictor for diabetes incidence)
1. Prediabetic state/
2. (prediabet* or pre diabet*).tw.
3. intermediate hyperglyc?emi*.tw.
4. or/1-3
5. incidence.sh. or exp mortality/ or follow-up studies.sh. or prognos*.tw. or predict*.tw. or course*.tw. [prognosis filter sensmax]
6. prognosis/ or diagnosed.tw. or cohort*.mp. or predictor*.tw. or death.tw. or exp models, statistical/ [prognosis filter bestbalance]
7. or/5-6
8. 4 and 7 [Population block (Prediabetes + Prognosis filter) ]
9. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw
10. (impaired glucose tolerance or IGT).tw.
11. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
12. or/9-11
13. (predict* or associa* or prognos*).tw.
14. ((prognostic or predict*) adj2 model?).tw.
15. predictive value?.tw.
16. (risk adj (predict* or factor? or score)).tw.
17. or/13-16
18. (((impaired fasting adj2 glucose) or IFG or “impaired FPG” or impaired glucose tolerance or IGT or “HbA(1c)” or HbA1 or
HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*)
adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block)]
19. 8 or 18 [Block 1 or block 2]
20. complication?.tw.
21. mortality.tw.
22. (CHD or CVD).tw.
23. (coronary adj2 disease).tw.
24. (coronar* adj (event? or syndrome?)).tw.
25. (heart adj (failure or disease? or attack? or infarct*)).tw
26. (myocardial adj (infarct* or isch?emi*)).tw.
27. cardiac failure.tw.
28. angina.tw.
29. revasculari*.tw.
30. (stroke or strokes).tw.
31. cerebrovascular.tw.
32. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
33. apoplexy.tw.
34. ((vascular or peripheral arter*) adj disease?).tw.
35. cardiovascular.tw.
36. (neuropath* or polyneuropath*).tw.
37. (retinopath* or maculopath*).tw.
38. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
39. ((kidney or renal) adj (disease? or failure or transplant*)).tw
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40. ((chronic or endstage or end stage) adj (renal or kidney)).tw
41. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
42. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
43. (cancer or carcino* or neoplas* or tumo?r?).tw.
44. (amputation? or ulcer* or foot or feet or wound*).tw.
45. or/20-44 [3rd block: outcomes]
46. 19 and 45
47. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [strategy B]
48. 19 and 47
49. 46 or 48
50. exp animals/ not humans/
51. 49 not 50
52. (gestational or PCOS).tw.
53. 51 not 52
54. (comment or letter or editorial).pt.
55. 53 not 54
56. remove duplicates from 55
Embase (Ovid SP)
Whole strategy (combining strategy A: ’prediabetes’ as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovas-
cular complications and strategy B: ’prediabetes’ as predictor for diabetes incidence)
1. (prediabet* or pre diabet*).tw.
2. intermediate hyperglyc?emi*.tw.
3. or/1-2
4. exp disease course or risk*.mp. or diagnos*.mp. or follow-up.mp. or ep.fs. or outcome.tw. [prognosis filter sensmax]
5. follow-up.mp. or prognos*.tw. or ep.fs. [prognosis filter bestbalance]
6. or/4-5
7. 3 and 6 [Population block (Prediabetes + Prognosis filter) ]
8. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw
9. (impaired glucose tolerance or IGT).tw.
10. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
11. or/8-10
12. (predict* or associa* or prognos*).tw.
13. ((prognostic or predict*) adj2 model?).tw.
14. predictive value?.tw.
15. (risk adj (predict* or factor? or score)).tw.
16. or/12-15
17. (((impaired fasting adj2 glucose) or IFG or “impaired FPG” or impaired glucose tolerance or IGT or “HbA(1c)” or HbA1 or
HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*)
adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block)]
18. 7 or 17 [block 1 or block 2]
19. complication?.tw.
20. mortality.tw.
21. (CHD or CVD).tw.
22. (coronary adj2 disease).tw.
23. (coronar* adj (event? or syndrome?)).tw.
24. (heart adj (failure or disease? or attack? or infarct*)).tw
25. (myocardial adj (infarct* or isch?emi*)).tw.
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26. cardiac failure.tw.
27. angina.tw.
28. revasculari*.tw.
29. (stroke or strokes).tw.
30. cerebrovascular.tw.
31. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
32. apoplexy.tw.
33. ((vascular or peripheral arter*) adj disease?).tw.
34. cardiovascular.tw.
35. (neuropath* or polyneuropath*).tw.
36. (retinopath* or maculopath*).tw.
37. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
38. ((kidney or renal) adj (disease? or failure or transplant*)).tw
39. ((chronic or endstage or end stage) adj (renal or kidney)).tw
40. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
41. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
42. (cancer or carcino* or neoplas* or tumo?r?).tw.
43. (amputation? or ulcer* or foot or feet or wound*).tw.
44. or/19-43 [3rd block: outcomes]
45. 18 and 44
46. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [strategy B]
47. 18 and 46
48. 45 or 47
49. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ [TSC
Portal filter for exclusion of animal references]
50. human/ or normal human/ or human cell/
51. 49 and 50
52. 49 not 51
53. 48 not 52
54. (gestational or PCOS).tw.
55. 53 not 54
56. (comment or letter or editorial or conference).pt.
57. 55 not 56
58. remove duplicates from 57
ClinicalTrials.gov (Expert search)
( prediabetes OR prediabetic OR “pre diabetes” OR “pre diabetic” OR “intermediate hyperglycemia” OR “intermediate hypergly-
caemia”OR “intermediate hyperglycemic”OR “intermediate hyperglycaemic”OR “impaired glucose tolerance”OR “impaired fasting
glucose” ) AND ( complication OR complications OR mortality OR CHD OR CVD OR coronary OR heart OR myocardial OR
infarct OR infarction OR infarcts OR infarctions OR ischemia OR ischemic OR ischaemia OR ischaemic OR failure OR angina OR
revascularization OR revascularisation OR revascularizations OR revascularisations OR stroke OR strokes OR cerebrovascular OR
apoplexy OR vascular or peripheral OR cardiovascular OR neuropathy OR neuropathies OR polyneuropathy OR polyneuropathies
OR retinopathy OR retinopathies OR maculopathy OR maculopathies OR nephropathy OR nephropathies OR nephrotic OR
proteinuria OR proteinuric OR albuminuria OR kidney OR renal OR CRD OR CRF OR CKF OR CRF OR CKD OR ESKD
OR ESKF OR ESRD OR ESRF OR microvascular OR macrovascular OR “micro vascular” OR “macro vascular” OR cancer OR
carcinoma OR neoplasmOR neoplasms OR tumor OR tumors OR tumour OR tumours OR amputation OR amputations OR ulcer
OR foot OR feet OR wounds OR ( diabetes OR diabetic OR “type 2” OR “type II” OR T2D OR T2DM ) AND ( progress OR
progression OR progressed OR incident OR incidence OR conversion OR developed OR development OR future ) ) [OUTCOME]
11Intermediate hyperglycaemia as a predictor for the development of type 2 diabetes: prognostic factor exemplar review (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
ICTRP Search Portal (Standard search)
prediabet* AND prognos* OR
prediabet* AND predict* OR
prediabet* AND inciden* OR
prediabet* AND mortality OR
prediabet* AND prevent* OR
prediabet* AND progress* OR
prediabet* AND develop* OR
pre diabet* AND prognos* OR
pre diabet* AND predict* OR
pre diabet* AND inciden* OR
pre diabet* AND mortality OR
pre diabet* AND prevent* OR
pre diabet* AND progress* OR
pre diabet* AND develop* OR
impaired glucose tolerance AND prognos* OR
impaired glucose tolerance AND predict* OR
impaired glucose tolerance AND inciden* OR
impaired glucose tolerance AND mortality OR
impaired glucose tolerance AND prevent* OR
impaired glucose tolerance AND progress* OR
impaired glucose tolerance AND develop* OR
impaired fasting glucose AND prognos* OR
impaired fasting glucose AND predict* OR
impaired fasting glucose AND inciden* OR
impaired fasting glucose AND mortality OR
impaired fasting glucose AND prevent* OR
impaired fasting glucose AND progress* OR
impaired fasting glucose AND develop* OR
HbA* AND prognos* OR
HbA* AND predict* OR
HbA* AND inciden* OR
HbA* AND mortality OR
HbA* AND prevent* OR
HbA* AND progress* OR
HbA* AND develop*
Appendix 2. QUIPS tool signalling questions
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Trial ID Trial ID
Signalling question Authors’ judgement for ’yes’
Study participation (STP) - yes/noa /unclearb/NAc Study participation
a. Adequate participation in the study by eligible persons NA: usually participants with intermediate hyperglycaemia or
with no diabetes at baseline are selected from a greater cohort on
another research question (e.g. cardiovascular risk factors in el-
derly people)
b. Description of the source population or population of interest Source population for cohort with intermediate hyperglycaemia
is clearly described
c. Description of the baseline study sample Number of people with intermediate hyperglycaemia at baseline
is clearly described
d. Adequate description of the sampling frame and recruitment Way of how the source population was established, selection cri-
teria and key characteristics of the source population clearly de-
scribed
e. Adequate description of the period and place of recruitment Time period andplace of recruitment for both baseline and follow-
up examinations are clearly described
f. Adequate description of inclusion and exclusion criteria Definiton of people with normoglycaemia, intermediate hyper-
glycaemia or diabetes mellitus and description of other in- and
exclusion criteria
STP risk of bias rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Study attrition (STA) - yes/no/unclear Study attrition (ST
a. Adequate response rate for study participants NA: usually participants with intermediate hyperglycaemia or
with no diabetes at baseline are selected from a greater cohort (e.
g. all obese people)
b. Description of attempts to collect information on participants
who dropped out
Attempts to collect information on participants who dropped out
are described (e.g. telephone contact, mail, registers)
c. Reasons for loss to follow-up are provided Reasons on participants who dropped out are available (e.g. de-
ceased participants between baseline and follow-up, participants
moving to another location)
d. Adequate description of participants lost to follow-up Key elements of participants lost to follow-up are described (age,
sex, glucose status at baseline, body mass index)
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(Continued)
e. There are no important differences between participants who
completed the study and those who did not
Study authors describe differences between participants complet-
ing the study and those who did not as not important or infor-
mation provided to judge the differences
STA risk of bias rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Prognostic factor measurement (PFM) - yes/no/unclear/NA Prognostic factor
a. A clear definition or description of the PF is provided Measurements for intermediate hyperglycaemia are provided (e.
g. IFG, IGT, elevated HbA1c)
b. Method of PF measurement is adequately valid and reliable Ideally measurements for intermediate hyperglycaemia are re-
peated to ensure diagnosis, single measurements are accepted as
well; technique for glucose measurement or HbA1c measurement
described
c. Continuous variables are reported or appropriate cut points are
used
Standard categories for intermediate hyperglycaemia (FPG 5.6-6.
9 mmol/L (IFG5.6), FPG 6.1-6.9 mmol/L (IFG6.1), 2-hr PG 7.
8-<11.0 mmol/L (IGT), HbA1c 6.0-6.4% (HbA1c6.0), HbA1c
5.7-6.4% (HbA1c5.7))
d. The method and setting of measurement of PF is the same for
all study participants
Measurements of intermediate hyperglycaemia are the same for
all study participants
e. Adequate proportion of the study sample has complete data for
the PF
NA: usually participants with intermediate hyperglycaemia or
with no diabetes at baseline are selected from a greater cohort (e.
g. proportion 100% because study focused on IGT-subcohort)
f. Appropriate methods of imputation are used for missing PF
data
NA: missing laboratory measurements for intermediate hypergly-
caemia cannot be reliably imputed
PFM risk of bias rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Outcome measurement (OM) - yes/no/unclear/NA Outcome measur
a. A clear definition of the outcome is provided Measurement of type 2 diabetes mellitus has to be defined
b. Method of outcome measurement used is adequately valid and
reliable
Measurement of type 2 diabetes mellitus: a glucose (FPG, PG)
or HbA1c measurement has to be a part of the diagnosis (self-
reported diabetes alone will not be accepted)
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c. The method and setting of outcome measurement is the same
for all study participants
Measurements of type 2 diabetes mellitus are the same for all study
participants
OM rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Study confounding (SC) - yes/no/unclear/NA Study confounding
a. All important confounders are measured Important confounders are: age, sex, family history of diabetes,
ethnicity, body mass index, blood pressure and hypertension,
smoking and drinking status, socioeconomic status, comedica-
tions and comorbidities, physical activity
b. Clear definitions of the important confounders measured are
provided
Measurement of confounders has to be clearly described
c. Measurement of all important confounders is adequately valid
and reliable
Measurement of confounders is valid and reliable
d. The method and setting of confounding measurement are the
same for all study participants
Measurements of confounders are the same for all study partici-
pants
e. Appropriate methods are used if imputation is used for missing
confounder data
Strategy to impute missing confounder data is described
f. Important potential confounders are accounted for in the study
design
Methods section of the publication describes strategy to account
for confounders
g. Important potential confounders are accounted for in the anal-
ysis
Important confounders are accounted for in multivariate logistic
regression and Cox proportional hazards models
SC risk of bias rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Statistical analysis and reporting (SAR) - yes/no/unclear/NA Statistical analysis
a. Sufficient presentation of data to assess the adequacy of the
analytic strategy
Mean ormedian values, including confidence intervals or standard
errors or standard deviations
b. Strategy for model building is appropriate and is based on a
conceptual framework or model
NA: we do not anticipate conceptual frameworks or explicitmodel
building strategies for this type of research question (focusing on
one prognostic factor only)
15Intermediate hyperglycaemia as a predictor for the development of type 2 diabetes: prognostic factor exemplar review (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
c. The selected statistical model is adequate for the design of the
study
Mainly incidence rates, uni- and multivariate logistic regression,
Cox proportional hazard model
d. There is no selective reporting of results NA: development of type 2 diabetes mellitus and potentially re-
gression to normoglycaemia from intermediate hyperglycaemia
are the only outcomes; if missing the study will be excluded
SAR risk of bias rating (high/low/unclear) High: majority of items is answered with ’no’; Low: all items
answered with ’yes’; Unclear: majority of items is answered with
’unclear
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
aNo: no or no relevant information to answer the signalling question
bUnclear: not enough information to answer signalling question with yes or no
cNA (not applicable): signalling question not appropriate for this type of prognostic review
FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance;
PG: post-load glucose (after an oral glucose tolerance test (OGTT))
aNo: no or no relevant
bUnclear: not enough
with yes or no
cNA (not applicable):
type of prognostic
FPG: fasting plasma
A1c; IFG: impaired
PG: post-load glucose
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